Index additions put AtaiBeckley in front of more institutional investors

AtaiBeckley (ATAI) is drawing fresh attention after being added to multiple Russell indexes, including the Russell 2000 and Russell 3000. This shift increases its visibility with institutional and index-tracking investors.

AtaiBeckley’s latest index additions come on the back of strong recent momentum, with a 1-day share price return of 15.5%, a 90-day share price return of 49.4%, and a 1-year total shareholder return of 141.6%. However, the 5-year total shareholder return is down 70.7%, indicating a much bumpier long-term journey.

If you are comparing AtaiBeckley’s move with other opportunities in high growth areas, this is a good moment to broaden your search and check out 20 top founder-led companies

With AtaiBeckley now included in multiple Russell indexes and the stock already up sharply over the past year, the key question is whether the recent price still leaves room for upside or whether the market is already fully reflecting expectations for future growth.

Price to book for AtaiBeckley: is the premium justified?

On a simple valuation check, AtaiBeckley trades on a P/B ratio of 9.8x, which is well above both its US pharmaceuticals industry peers and the narrower peer group used in the analysis.

The price to book ratio compares the company’s market value to its net assets on the balance sheet. For an early stage, clinical biopharmaceutical company like AtaiBeckley, a high P/B ratio typically reflects investor focus on future pipeline potential rather than current revenue or earnings, especially when the business is still loss making.

Here, the gap is wide. AtaiBeckley’s 9.8x P/B compares with an industry average of 2.3x and a peer average of 5.8x. This means the stock trades at more than four times the broader sector level and at a premium to closer peers. Without a fair ratio benchmark from regression analysis, there is limited guidance on where that multiple could settle over time. The current figures indicate that the market is already assigning a rich valuation to the company’s equity.

Result: Price to book ratio of 9.8x (OVERVALUED)

However, AtaiBeckley’s rich P/B multiple sits against a very small revenue base of $3.488 million and a reported net loss of $663.398 million, which could weigh on sentiment.

Next Steps

Given the mix of strong recent returns and a rich valuation for AtaiBeckley, it makes sense to check the underlying data yourself and move quickly to form your own view based on the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond AtaiBeckley?

After reviewing AtaiBeckley, it may be useful to widen your watchlist so you are not relying on a single story when there are many other potential opportunities.

• Target income potential by scanning for companies with resilient payouts through the 8 dividend fortresses.
• Focus on quality and value by reviewing companies screened as 44 high quality undervalued stocks.
• Seek stability by checking companies filtered as 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.